Evotec SE

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass. & HAMBURG, Germany--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO), a leading life science company, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts

EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND ACCESSIBLE MEDICINES TO PATIENTS HAMBURG, GERMANY, and CAMBRIDGE, MA / ACCESSWIRE / November 18, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas.

Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership

Evotec SE (EVOTF) CEO Werner Lanthaler on Q3 2021 Results - Earnings Call Transcript

STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH CO-OWNED PIPELINE GAINING MOMENTUM J.POD (R) REDMOND (US) OPERATIONAL SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END) GUIDANCE FOR FULL-YEAR 2021 CONFIRMED WEBCAST AND CONFERENCE CALL TODAY AT 02.00 PM CET HAMBURG, GERMANY / ACCESSWIRE / November 11, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2021. HIGHLIGHTS STRONG REVENUES GROWTH IN ALL BUSINESS AREAS FUELS ONGOING EXPANSION AND STRENGTHENS POSITIVE DEVELOPMENT Group revenues increased by 20% to € 431.0 m (9M 2020: € 360.4 m); like-for-like base revenue growth (excluding portfolio and fx effects) up 26% Milestone revenues of € 27.9 m well above last year (9M 2020: € 8.4 m) Just - Evotec Biologics contributed € 34.7 m to revenues; 43% above last year's level of € 24.3 m Strong progress in both segments: Total EVT Execute revenues up 17% to € 429.8 m (9M 2020: € 367.5 m); EVT Innovate revenues up 35% to € 101.9 m (9M 2020: € 75.7 m) Adjusted Group EBITDA of € 70.1 m (9M 2020: € 76.9 m) primarily driven by higher costs of sales ahead of production start of J.POD (R) Redmond (US), a deliberate increase in unpartnered R&D (up 28%), the overall growth of Evotec and effects from the US public offering; like-for-like growth (excluding portfolio and fx effects) would have reached 16%.

Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update

THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / November 10, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809, NASDAQ:EVO) announced today that the Company reached additional programme designations within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering payments of in total US$ 40 m to Evotec. These target-based programme designations further bolster the growing pipeline and are expected to follow EVT8683, which Bristol Myers Squibb opted to license after the successful filing of an IND application with the FDA.

Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb

HAMBURG, GERMANY / ACCESSWIRE / November 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today the closing of its public offering on 08 November 2021 in the United States of 20,000,000 American Depositary Shares ("ADSs"). Each ADS represents half of one ordinary share of Evotec.

Evotec SE Announces Closing of Public Offering

HAMBURG, GERMANY / ACCESSWIRE / 3 November 2021 / Evotec SE's (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) management board today decided - with the approval of its supervisory board - on the volume and the issue price of its public offering of American Depositary Shares ("ADSs"). The offering will produce gross proceeds of $ 435,000,000 from the sale of 10,000,000 ordinary shares of Evotec in the form of 20,000,000 ADSs at a price of $ 21.75 per ADS.

Evotec SE Announces Placement of Its Public Offering of American Depositary Shares

HAMBURG, GERMANY / ACCESSWIRE / November 3, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first nine months 2021 on Thursday, 11 November 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance.

Evotec SE To Announce Results for the First Nine Months 2021 On 11 November 2021

Evotec SE has filed to raise $576 million in a U.S. IPO.

Evotec SE Targets $576 Million U.S. IPO

Evotec is a leading drug discovery and development partner for the pharmaceutical and biotechnology industry.

Evotec: Data-Driven R&D Company Filing New IPO

German biotech Evotec SE (OTC: EVTCY) plans to raise $576 million by offering 22 million ADSs at $26.16. At the proposed price, Evotec would command a market value of $9.2 billion.

Germany Based Evotec Sets Terms For $576M US IPO

HAMBURG, GERMANY / ACCESSWIRE / October 26, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has commenced a public offering in the United States of up to 22,000,000 American Depositary Shares ("ADSs") representing 11,000,000 of its ordinary shares pursuant to a registration statement on Form F-1, as amended, filed with the U.S. Securities and Exchange Commission ("SEC"). Evotec expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ADSs.

Evotec SE: Announces Launch of Public Offering of American Depositary Shares

9M 2021 REVENUES EXPECTED TO BE IN THE RANGE OF € 425 - 435 M ADJUSTED 9M 2021 EBITDA EXPECTED TO BE IN THE RANGE OF € 68 - 72 M THE FIGURES IN THIS ANNOUNCEMENT ARE PRELIMINARY AND SUBJECT TO CHANGE THE COMPLETE 9M 2021 INTERIM FINANCIAL RESULTS WILL BE RELEASED AS SCHEDULED ON 11 NOVEMBER 2021 HAMBURG, GERMANY / ACCESSWIRE / October 26, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), today reported preliminary and unaudited results for the first nine months ended 30 September 2021. Evotec expects revenues from contracts with customers for the first nine months of 2021 to be in the range of € 425 - 435 m; significantly above the € 360.4 m posted in the prior year's period.

Evotec Provides Preliminary Nine Month Financial Results

Pasithea Therapeutics Corp

-- Company contracts leading global drug development company to advance initial drug candidate -- -- Company contracts leading global drug development company to advance initial drug candidate --

Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement

HAMBURG, GERMANY / ACCESSWIRE / October 11, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed offering and sale in the United States of shares of Evotec represented by American Depositary Shares ("ADSs"). The Registration Statement has not yet become effective and the final number of ADSs to be offered and their price have not yet been determined.

Evotec SE files Registration Statement for Proposed Offering of American Depositary Shares

Allstate

Roundhill Sports Betting & iGaming ETF

VanEck Vectors Gaming ETF

DraftKings

Global Eagle Entertainment

Las Vegas Sands

MGM Resorts

Rush Street Interactive

Sometimes a larger playing field is what it takes to score.

Here Are 2 Great Ways to Make an Investment in Online Betting Less Risky

DEFINING CLEAR DEVELOPMENT PATHWAY FOR NEXT GENERATION OF PSYCHEDELIC MEDICINES TO TREAT ADDICTIONToronto, Ontario--(Newsfile Corp. - April 27, 2021) - Awakn Life Sciences Inc. (Awakn), a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicines to treat Addiction, announced today the initiation of a new chemical entity (NCE) development program to strengthen Awakn's pipeline for the treatment of a broad range of addictions. The Company has also announced the appointment of Evotec as NCE research partner and the selection of Prof. David Nutt, one of...

Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec as Research Partner and Addiction Expert, Prof. David Nutt, as Program Lead

The software and gambling company is the backbone behind many popular online casinos.

Is Evolution Gaming a Stock for the Long Haul?

HAMBURG, GERMANY / ACCESSWIRE / January 7, 2021 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences in the first quarter of 2021: J.P. Morgan 39th Annual Healthcare Conference 2021 Date: Monday, 11 January - Thursday, 14 January 2021             Presentation: Tuesday, 12 January, 7.30 am EST (1.30 pm CET, 12.30 pm GMT, 4.30 am PST) Venue: Virtual Attendee: Werner Lanthaler, Chief Executive Officer Commerzbank German Investment Seminar Date: Wednesday, 13 January 2021 Venue: Virtual Attendee: Werner Lanthaler, Chief Executive Officer UniCredit Kepler Cheuvreux German Corporate Conference Date: Wednesday, 20 January 2021             Presentation: Wednesday, 20 January, 12 pm CET Venue: Virtual Attendee: Werner Lanthaler, Chief Executive Officer BioCapital Europe Date: Thursday, 11 March 2021 Venue: Virtual Attendee: Enno Spillner, Chief Financial Officer ABOUT EVOTEC SE Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

Evotec To Attend Upcoming Investor Conferences

EVOTEC GAINS ACCESS TO ALLOY THERAPEUTICS' ATX-GX(TM) HUMANISED MICE PLATFORM FOR BIOLOGICS DISCOVERY PARTNERSHIP LEVERAGES COMPLEMENTARY STRENGTHS OF IN SILICO, IN VITRO AND IN VIVO ANTIBODY DISCOVERY IN A RANGE OF INDICATIONS HAMBURG, GERMANY / ACCESSWIRE / December 21, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Alloy Therapeutics ("Alloy"), a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec's antibody discovery platform. Under the terms of the agreement, Evotec receives access to Alloy's ATX-Gx(TM) mouse platform to enable best-in-class in vivo discovery of fully human monoclonal antibodies for use in both its proprietary as well as partnered R&D projects across more than 15 disease areas.

Evotec Partners with Alloy Therapeutics to Expand its Antibody Discovery Platform

In an announcement on Thursday, Evotec (ETR: EVT) said that it has acquired the U.S-based biologics company Just Biotherapeutics. The U.S. company is financially backed by the Gates Foundation.

News for Evotec SE Stock (EVO)